Medicare beneficiaries are concerned. The new year is bringing higher premiums, higher deductibles, and growing uncertainty about their medical coverage. Medicare open enrollment for 2026 closed on December 7 so for most beneficiaries, coverage decisions are locked in.
What isn’t locked in is what they’ll pay.
When 2026 begins, Medicare recipients will step into a year with higher premiums, higher deductibles, and continued uncertainty around their prescription drug coverage. The structural cost pressures outlined this fall will soon be operational reality.
The Cost Environment Has Tightened
Several changes are converging at once:
- The standard Part B premium jumps to $206 per month, a 12% increase that outpaces Social Security cost-of-living adjustments.
- Deductibles for both Part B and Part D go up.
- The annual out-of-pocket cap for Part D drugs increases to $2,100.
- During the most recent enrollment cycle, fewer Part D plans were offered, concentrating market power and enabling narrower formularies that will increasingly shift prescription cost risk onto beneficiaries.
Though some premiums dipped modestly on paper, the fine print could mean beneficiaries will spend more out-of-pocket. Coverage changes, tier shifts, and utilization patterns often tell a different story once prescriptions are filled.
Prescription Drugs Remain the Primary Wild Card
Roughly 81% of Medicare beneficiaries rely on Part D coverage. While CMS negotiations are expected to lower prices for a small set of high-profile drugs, many others remain expensive and volatile, particularly specialty medications, orphan drugs, and therapies excluded from negotiation.
Even when list prices fall, beneficiaries may still face:
- Higher cost-sharing due to formulary or tier changes
- Limited alternatives when coverage shifts midyear
- Increased pressure to substitute medications quickly
For seniors on fixed incomes, these dynamics often result in delayed fills, dose skipping/halving, or outright abandonment.
At this point in the year, beneficiaries cannot change plans to solve these problems. The only remaining lever is medication strategy.
Why Plan Design Alone Isn’t Enough
During open enrollment, beneficiaries were urged to compare plans carefully, and that guidance was appropriate at the time. Those choices are now locked in. The financial risk has moved downstream, to the moment prescriptions meet formularies, coverage rules, and real-world patient behavior. In 2026, affordability will be shaped less by which plan someone chose and more by whether every medication they take still delivers clinical value at a sustainable cost.
How RazorMetrics Reduces In-Year Risk
RazorMetrics operates where plan design stops working: inside the prescribing process, within normal clinical workflows.
Instead of reacting after costs surface, we help physicians identify opportunities to reduce unnecessary or high-cost medications to lower the financial burden. That includes:
- Therapeutic alternatives when clinically appropriate
- Deprescribing medications that no longer provide value
- Biosimilar opportunities that preserve outcomes while lowering cost
- Polypharmacy reviews that reduce adverse events and downstream utilization
When a medication is deprescribed or appropriately switched, the savings are durable. The plan avoids the full ongoing cost of that drug. The member avoids unnecessary expense, side effects, and complexity.
In a year where premiums are rising and coverage flexibility has narrowed, those savings matter more than ever.
The 2026 Reality
Open enrollment has passed. Beneficiaries are living with the consequences. The dependable path forward is through active optimization of what’s being prescribed today, tomorrow, and all year long.
In 2026, affordability will be determined by whether prescriptions are clinically appropriate, cost-effective, and still necessary within the coverage beneficiaries already have. RazorMetrics is here to make affordability a reality.
